Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group Identifier:
First received: June 5, 2010
Last updated: May 17, 2016
Last verified: May 2016

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is studying blood and tumor tissue samples from young patients with acute myeloid leukemia.

Condition Intervention
Genetic: gene expression analysis
Genetic: western blotting
Other: flow cytometry
Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Evaluation of Mer and Axl Expression in Acute Myeloid Leukemia Patient Samples

Resource links provided by NLM:

Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Expression of Mer and Axl
  • Association of abnormal expression of Mer and Axl with induction failure or relapse

Biospecimen Retention:   Samples With DNA
blood and tumor samples

Estimated Enrollment: 52
Study Start Date: September 2009
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Detailed Description:


  • To evaluate Mer and Axl expression in samples from pediatric patients with acute myeloid leukemia (AML).
  • To determine if abnormal expression of Mer and Axl is associated with poor clinical characteristics (e.g., induction failure or relapse) of AML in these patients.

OUTLINE: This is a multicenter study.

Archived samples from pediatric patients with acute myeloid leukemia are analyzed for Mer and Axl expression by flow cytometry and western blot assays.


Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diagnosis of acute myeloid leukemia


  • Diagnosis of acute myeloid leukemia
  • Children Oncology Group (COG) patient samples


  • Available clinical data


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01139333

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Kristen M. Eisenman, MD University of Colorado, Denver
  More Information

Responsible Party: Children's Oncology Group Identifier: NCT01139333     History of Changes
Other Study ID Numbers: AAML10B4
COG-AAML10B4 ( Other Identifier: Children's Oncology Group )
CDR0000671452 ( Other Identifier: Clinical )
NCI-2011-02222 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Study First Received: June 5, 2010
Last Updated: May 17, 2016

Keywords provided by Children's Oncology Group:
childhood acute myeloid leukemia/other myeloid malignancies

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms processed this record on May 25, 2017